WEIGHT MANAGEMENT
Semaglutide
A once-weekly GLP-1 receptor medication used with nutrition and follow-up care for eligible adults managing weight.
What it is
Semaglutide is a prescription GLP-1 receptor agonist that may be used for chronic weight management in eligible patients. It is paired with medical screening, nutrition guidance, and follow-up.
How it works
It acts on GLP-1 pathways involved in appetite, fullness, and blood-glucose regulation. The dose is increased gradually when appropriate to improve tolerability. A clinician reviews contraindications, side effects, weight trend, and metabolic markers throughout treatment.
Who it is for
- Adults who meet medical criteria for prescription weight management
- Patients ready to pair medication with nutrition and activity changes
- Patients able to attend dose-titration and monitoring visits
Mechanism in depth
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone that signals fullness to the brain, slows gastric emptying, and increases insulin secretion when blood sugar is high. Semaglutide mimics native GLP-1 but with a long half-life that allows once-weekly dosing. Over months, most patients experience reduced appetite, reduced food noise, and gradual weight loss when paired with diet and exercise.
What outcomes to expect
Appetite reduction often begins within one to two weeks. Meaningful weight loss usually shows up over three to six months, with the average patient losing a substantial portion of body weight over a year of treatment. Response varies significantly — genetics, adherence, dose tolerance, diet, and activity level all matter.
Individual response varies. GPLX does not guarantee results. Your physician sets expectations based on your health history and lab findings.
Common side effects
The most common side effects are nausea, constipation, diarrhea, occasional vomiting, injection site reaction, and heartburn — especially during dose escalation. Serious but rare concerns include pancreatitis, gallbladder events, and, in animal studies, thyroid C-cell tumors. Muscle loss during rapid weight loss requires attention to protein intake and resistance training.
Monitoring schedule
Baseline labs, then follow-up at four weeks after the initial dose and after each dose increase. Ongoing monitoring occurs monthly during titration, then every three months. Weight, blood pressure, HbA1c, and metabolic markers are tracked at each visit.
Not appropriate if
Not appropriate if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe gastroparesis, uncontrolled diabetic retinopathy without ophthalmology involvement, or if pregnancy is possible or planned in the near term.
Biomarkers reviewed with this treatment
Your physician reviews these markers before and during therapy. Click any marker for a plain-English explanation of what it measures and why it matters.
This treatment is only available after a physician consultation. Membership $39.99/month; consultation $30. Labs and medications billed separately.
Start Your Consultation